Eli Lilly and Company (“Lilly”) announced the
launch of its latest cardiovascular product, “Effient” (Prasugrel) in India.
Effient is an oral anti-platelet (OAP) agent that has been approved for
patients with Acute Coronary Syndrome (ACS) who have undergone angioplasty
procedures. Antiplatelet medicines help keep platelets from sticking together
that can cause blockage in an artery, thereby reducing the risk of future heart
attacks and recurrent hospitalization.
India has the highest burden of heart disease in the world. According to the Lancet, by 2010, 60% of the world's heart disease is expected to occur in India. Effient, which was co-developed with Daiichi Sankyo Limited, has been launched in around 70 countries till date. The treatment is already recommended under the ACC (American College of Cardiology), AHA (American Heart Association) and more recently in the ESC (European Society of Cardiology) and the NICE (National Institute of Clinical Excellence) guidelines.
India has the highest burden of heart disease in the world. According to the Lancet, by 2010, 60% of the world's heart disease is expected to occur in India. Effient, which was co-developed with Daiichi Sankyo Limited, has been launched in around 70 countries till date. The treatment is already recommended under the ACC (American College of Cardiology), AHA (American Heart Association) and more recently in the ESC (European Society of Cardiology) and the NICE (National Institute of Clinical Excellence) guidelines.
No comments:
Post a Comment